Richard Ruh, MD
Family Medicine · Orchard Park, NYNPI 1073535449
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Kestra Medical Technology Services, Inc. at 26.0% of the total. Reporting peaked in 2023 at $833 and has fallen 72.9% since, to $226 in 2025.
Across 72 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kestra Medical Technology Services, Inc.$453
- AbbVie$288
- Lilly USA, LLC$213
- Abbott$165
- Pfizer$121
- Novo Nordisk$99
- plus $404 from 13 others
Across 144 payments — averaging $5326.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$313K
- Regeneron$234K
- Ironwood Pharmaceuticals, Inc$73K
- AstraZeneca$71K
- Amgen$38K
- Ionis Pharmaceuticals, Inc.$17K
- plus $21K from 2 others
What the payments were for
- Food & beverage$1,743100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kestra Medical Technology Services, Inc. | 5 | $453 |
| AbbVie | 15 | $288 |
| Lilly USA, LLC | 7 | $213 |
| Abbott | 11 | $165 |
| Pfizer | 6 | $121 |
| Novo Nordisk | 5 | $99 |
| GSK | 5 | $88 |
| AstraZeneca | 3 | $65 |
| Merck | 4 | $65 |
| Exact Sciences | 1 | $29 |
| Amgen(2 entities) | 2 | $25 |
| Inari Medical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $18 |
| Dermira, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assure WCD$266
- MOUNJARO$111
How this compares
$1,743 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 62 | $77,685 |
| EliquisApixaban | 71 | $64,088 |
| JardianceEmpagliflozin | 20 | $30,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $23,178 |
| FarxigaDapagliflozin Propanediol | 23 | $16,783 |
| MounjaroTirzepatide | 16 | $15,161 |
| OzempicSemaglutide | 15 | $14,021 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 57 | $12,722 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,575 |
| Metoprolol Succinate | 277 | $6,107 |
| Atorvastatin Calcium | 390 | $5,650 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $5,263 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $5,033 |
| Levothyroxine Sodium | 277 | $4,983 |
| Rosuvastatin Calcium | 339 | $4,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $213 | $92,84678 claims |
| PfizerEliquis | $121 | $64,08871 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Arnuity Ellipta | $88 | $45,961115 claims |
| Boehringer IngelheimJardiance | $18 | $30,03920 claims |
| AstraZenecaFarxiga | $65 | $16,78323 claims |
| Novo NordiskOzempic | $99 | $14,02115 claims |
| AbbVieSynthroid | $288 | $2,16638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.
Other family medicine in Orchard Park
- Thomas DilamarterOrchard Park$42K
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.